← Back to Treatments
🏅 FDA Orphan Designation

Vonvendi

von Willebrand factor (recombinant)

Manufacturer: Takeda Pharmaceuticals U.S.A., Inc.

Indicated for:
Pseudo-von Willebrand diseaseOrphanVon Willebrand disease type 3

FDA-Approved Indications (2)

For use in adults (age 18 and older) diagnosed with von Willebrand disease (VWD) for routine prophylaxis to reduce the frequency of bleeding episodes in patients with severe Type 3 VWD receiving on-de…

For use in adults (age 18 and older) diagnosed with von Willebrand disease (VWD) for routine prophylaxis to reduce the frequency of bleeding episodes in patients with severe Type 3 VWD receiving on-de…

Population: adults (age 18 and older)

Indications & Usage

For use in adults (age 18 and older) diagnosed with von Willebrand disease (VWD) for routine prophylaxis to reduce the frequency of bleeding episodes in patients with severe Type 3 VWD receiving on-demand therapy ||| in adult and pediatric patients with von Willebrand disease (VWD) for on-demand treatment and control of bleeding episodes, and perioperative management of bleeding; and for adults for routine prophylaxis to reduce the frequency of bleeding episodes

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.